Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:PRVL

Prevail Therapeutics (PRVL) Stock Price, News & Analysis

Prevail Therapeutics logo

About Prevail Therapeutics Stock (NASDAQ:PRVL)

Key Stats

Today's Range
$23.00
$23.00
50-Day Range
$22.91
$23.20
52-Week Range
$9.02
$23.35
Volume
N/A
Average Volume
955,800 shs
Market Capitalization
$787.66 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Prevail Therapeutics Inc., a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. The company's lead product candidate is PR001, which is in Phase I/II clinical trial for the treatment of Parkinson's disease with GBA1 mutation and neuronopathic Gaucher disease. It is also developing PR006 for the treatment of frontotemporal dementia with GRN mutation; and PR004 for the treatment of synucleinopathies. Prevail Therapeutics Inc. was founded in 2017 and is based in New York, New York.

Receive PRVL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Prevail Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PRVL Stock News Headlines

917 Trades… Zero Losses?
As you likely know, the “Trump bump” launched stocks to record highs after he secured his second reelection bid. Now, Trump and his team are coming to gut government regulation – and it’s going to create some incredible market opportunities. But while the masses chase large-cap tech and so-called AI stocks, a small circle of traders are using a strange but tactical method to find a pool of “hidden Trump trades.”
See More Headlines

PRVL Stock Analysis - Frequently Asked Questions

Prevail Therapeutics Inc. (NASDAQ:PRVL) issued its quarterly earnings results on Friday, November, 13th. The company reported ($0.55) EPS for the quarter, topping the consensus estimate of ($0.64) by $0.09.

Prevail Therapeutics (PRVL) raised $126 million in an initial public offering (IPO) on Thursday, June 20th 2019. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen and Company served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Prevail Therapeutics investors own include NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Editas Medicine (EDIT), Alector (ALEC), Advanced Micro Devices (AMD), Atreca (BCEL) and Homology Medicines (FIXX).

Company Calendar

Last Earnings
11/13/2020
Today
11/21/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological Products, Except Diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:PRVL
CIK
N/A
Fax
N/A
Employees
66
Year Founded
N/A

Profitability

Net Income
$-63,190,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.85 per share

Miscellaneous

Free Float
N/A
Market Cap
$787.66 million
Optionable
Not Optionable
Beta
1.59
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

This page (NASDAQ:PRVL) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners